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Purpose: The purpose of the present study was to investigate the aberrance of his-
tone H3 lysine 4 trimethylation (H3K4me3) in patients with IgA Nephropathy 
(IgAN). Materials and Methods: In this study, H3K4me3 variations in peripheral 
blood mononuclear cells (PBMCs) from 15 IgAN patients and 15 healthy subjects 
were analyzed using chromatin immunoprecipitation linked to microarrays analy-
sis (ChIP-chip). ChIP real-time PCR was used to validate the microarray results. 
Expression analysis by quantitative real-time PCR (qRT-PCR) revealed correla-
tions between mRNA and H3K4me3 levels. DNA methylation status was ana-
lyzed by quantitative methylation-specific PCR. Results: We found that 321 
probes displayed significant H3K4me3 differences in IgAN patients compared 
with healthy controls. Among these probes, 154 probes displayed increased H3K-
4me3 and 167 probes demonstrated decreased H3K4me3. For further validation, 
we selected 4 key relevant genes (FCRL4, GALK2, PTPRN2 and IL1RAPL1) to 
study. The results of ChIP real-time PCR coincided well with the microarray data. 
Quantitative RT-PCR revealed the correlations between the mRNA expression and 
the methylation levels of H3K4me3. Different degrees of DNA methylation altera-
tions appeared on the selected positive genes. Conclusion: Our studies indicated 
that there were significant alterations in H3K4me3 in IgAN patients. These find-
ings may help to explain the disturbed immunity and abnormal glycosylation in-
volved in IgAN patients.
Key Words:    Chromatin immunoprecipitation, histone H3 lysine 4, IgA nephropa-
thy, quantitative methylation-specific PCR, trimethylation
INTRODUCTION
IgA Nephropathy (IgAN) is defined immunohistologically by predominant mesan-
gial deposition of IgA.1 The immunochemical nature of the IgA molecule and its 
mesangial uptake command a pivotal role in the pathogenesis of IgAN.2,3 Many Suwen Qi, et al.
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in yeast. In humans, Weinmann, et al.20 first utilized chroma-
tin immunoprecipitation and CpG microarrays to identify 
target genes for transcription factors. Recently, this approach 
has been employed successfully to elucidate the profiles of 
H3K9 and H3K27 methylation in human disease.21-23
Promoter methylation profiling is quickly becoming a 
powerful diagnostic tool for the early detection, prognosis, 
and even prediction of a clinical response to treatments of 
various diseases. Among the theories concerning the etiolo-
gy of IgAN, little is known about the epigenetic alterations 
that occur.
Hence, in this study, we used ChIP-chip technology to pro-
file the variations in H3K4me3 at a genome-wide level of 
PBMCs from IgAN patients and healthy controls. Our aim 
was to gain better understanding of the pathogenic mecha-
nisms in IgAN. Meanwhile, we also researched the rele-





IgAN patients (n=15) and healthy volunteers (n=15) were 
recruited for this study. Patients were diagnosed and treated 
in the Kidney Transplantation and Hemopurification Center 
of the 181th Hospital of Guangzhou Military Area of PLA, 
from January 2006 to May 2009. Diagnostic criteria of IgAN 
were based on the manifestation of generalized glomerular 
mesangial proliferation, with the presence of IgA as the sole 
or predominant immunoglobulin deposited in the mesangial 
area of the glomeruli. All of the patients had undergone a re-
nal biopsy for an exact histological diagnosis. Renal biopsy 
specimens were graded as Haas I-V according to the patho-
logical scheme of IgAN proposed by Haas.24 Age-, race- and 
patients with IgAN have elevated levels of aberrantly gly-
cosylated IgA1 in circulating immune complexes.4,5 Aber-
rant IgA1 O-glycosylation results from the abnormal func-
tion or expression of several specific glycosyltransferases, 
which may be one of the key pathogenetic mechanisms of 
IgAN.6 It was also thought that the pathogenic potential of 
frequently colocalized IgG deposits depends on polarized 
T-helper cytokines that modulate Fcα receptors of infiltrat-
ing macrophages, leading to either activation or inhibition 
that determines glomerular injury.7 How this kind of im-
mune dysregulation and over-production of aberrantly gly-
cosylated IgA1 develops remain obscure.8 Histone lysine 
methylation is an important epigenetic mechanism for gene 
silencing, which may confer tumor cells of growth advan-
tage.9 Many cellular pathways are inactivated by this epi-
genetic event, including DNA repair, cell cycle, apoptosis, 
cell adherence, and detoxification.10 Lysine can accept 3 
methyl groups, and therefore can be monomethylated, di-
methylated or trimethylated. Methylation of histone H3 on 
lysine 4 (H3K4) plays an important role in the association 
with active chromatin and gene expression.11-14 Trimethyl-
ated H3K4 is preferentially detected at active genes and 
proposed to promote gene expression through recognition 
by transcription-activating effector molecules.13 Aberrant 
alterations in histone lysine methylation patterns implicate 
in multiple biological processes, such as changing the chro-
matin structure, regulating gene transcription.15,16 Therefore, 
it is of significant interest to discuss the aberrance of H3K-
4me3 in peripheral blood mononuclear cells (PBMCs) of 
IgAN patients and explore its pathogenic mechanisms.
Chromatin immunoprecipitation linked to microarrays 
analysis (ChIP-chip), with high-throughput capability, is a 
useful technology to study histone modifications at a ge-
nome-wide level.17,18 Ren, et al.19 first adopted this method 
to monitor binding of gene-specific transcription activators 
Table 1. Characteristics of Immunoglobulin A Nephropathy Patients and Healthy Controls
Characteristics  IgAN patients (n=15) Healthy subjects (n=15)
Male/Female  9/6  9/6
Age (yrs)   32.56±9.32  34.06±6.51 
Plasma albumin (g/L) 26.80±4.81    45.23±13.39 
Proteinuria (g/24 h)   4.89±1.38 Negative 
Serum creatinine (μmol/L) 103.71±45.84   68.36±15.68
Hass grade  4 (III)   -
 6 (IV)   -
5 (V)   -
IgAN, IgA Nephropathy.
Values are expressed as means±SD. H3K4me3 Alterations in IgAN 
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magnetic beads were sequentially washed in low salt, high 
salt, LiCl salt, and TE buffers. The protein/DNA complexes 
were eluted, and heated at 65°C for 5 hr to reverse formal-
dehyde crosslink. Samples were mixed with RNase for 20 
min at 37°C prior to treatment with proteinase K overnight. 
DNA was extracted according to the phenol/chloroform 
method. PCR amplification of DNA was carried out on di-
luted DNA aliquots as recommended by the whole genome 
amplification kit (Sigma, St. Louis, MO, USA) instructions, 
followed by DNA purification using the QIAquick PCR 
purification kit (Qiagen, Hilden, Germany). Cy5TM-dUTP 
and Cy3TM-dUTP (Invitrogen, Carlsbad, CA, USA) la-
beled methylated K4 precipitated DNA and input DNA, re-
spectively; and the products thereof were then cohybridized 
to the human 12K CpG-island array (UNH Microarray 
Centre, Toronto, Canada). The hybridized microarray slides 
were then scanned using a GenePix 4000B scanner (Axon 
Instruments, Foster City, CA, USA). GenePix pro version 
6.0 was used to read the raw intensity of the image. The re-
sulting text files were imported into the Agilent GeneSpring 
GX software for further analysis. The two microarray data 
sets were normalized in GeneSpring GX using the Agilent 
Two-color scenario (mainly LOWESS normalization), and 
then CpGs marked present (“All Targets Value”) were cho-
sen for further analysis. The differences between the test 
and control samples were identified using 2-fold change. 
The sequences of CpG islands on the array and alignment 
data are available at http://data.microarrays.ca/. The experi-
ments were done in duplicate.
Chromatin immunoprecipitation-quantitative PCR 
ChIP was conducted in the same way as in ChIP-chip. The 
DNA pool from ChIP, input control and negative control, 
was used for quantitative PCR which was performed on an 
ABI 7700 Real-Time PCR (Applied Biosystems, Foster 
City, CA, USA). The PCR conditions were as follows: an 
initial step of 95°C for 5 min, followed by 95°C for 15 sec,   
59°C for 20 sec, 72°C for 20 sec repeated for 40 cycles, and 
a final 10 min extension at 72°C. In order to evaluate ChIP 
on chip data, four genes were selected and their correspond-
ing primers are displayed in Table 2. Threshold cycle (CT) 
values of serially diluted input DNA were determined to 
generate a standard curve for each amplification. The H3K-
4me3 changes were determined using the 2-ΔΔCT method28 
and each reaction was performed with melting curve analy-
sis to ensure a single peak. The experiment was conducted in 
triplicate, and average value was calculated for each sample.
sex-matched healthy controls were recruited through adver-
tising. Urinalysis results of the healthy controls were nega-
tive and their serum creatinine was within the normal range. 
The clinical features of the patients and healthy subjects are 
shown in Table 1. The Ethics Committee of the Chongqing 
Medical University approved the study, and peripheral blood 
samples were obtained with the informed consent of all par-
ticipating individuals. The Helsinki Declaration was ad-
hered to throughout the study.
Isolation of PBMCs
Approximately 10 mL heparinized venous blood samples 
from IgAN patients and healthy volunteers were collected. 
Blood samples were treated according to the Ficoll-Paque 
Plus (Cedarlane Laboratoryies Ltd., Ontario, Canada) instruc-
tions and reference.25 Each sample was diluted with equal 
volumes of phosphate-buffered saline. The diluted blood was 
overlaid on the equal volume of Ficoll-Paque Plus medium, 
followed by centrifuged at 800 g for 25 min at 22°C. After 
being washed twice with phosphate-buffered saline, the col-
lected PBMC layer was stored at -80°C until assayed.
Chromatin immunoprecipitation microarray
The ChIP-chip analysis was performed according to de-
scribed protocols26,27 with some modifications. Firstly, 
PBMCs were allowed to crosslink with 1% formaldehyde 
(final concentration) for 10 min at 37°C, adding glycine 
(0.125 M) for 5 min at 37°C to stop the crosslink. Secondly, 
the cell pellets were eluted twice with 10 mL of ice-cold 1× 
PBS and then resuspended with 300 µL lysis buffer (10 
mM Tris-HCl pH 8.0; NaCl 100 mM; EDTA 1 mM pH 8.0; 
Na-Deoxycholate 0.1% and Protease inhibitors) and incu-
bated on ice for 30 min. Finally, the cell suspension was 
sonicated for 4 min (30 seconds “ON” & 30 seconds “OFF”) 
DNA lengths were decreased to between 200 and 1000 bp. 
Each ChIP sample was incubated  with 555 μL of dilution 
buffer containing a protease inhibitor cocktail, and the ly-
sate was then divided into three parts. The first lysate was 
incubated with anti-K4 trimethylated histone H3 antibody 
(Upstate Biotechnology, Lake Placid, NY, USA) at 4°C 
overnight. The remaining two parts served as the input con-
trol and negative control, respectively. Fifty microlitres of 
magnetic beads (Bangs Laboratories. Inc., Fishers, IN, 
USA) were added and incubated for 1 h at 4°C to harvest 
immunoprecipitated complexes. Pellet beads were ad-
sorbed to the bottom of the tube by a magnetic separation 
rack for 2 min at 4°C, and then discard the supernatant. The Suwen Qi, et al.
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10 min for extension. Expression was assessed by evaluat-
ing CT values. The relative quantity of expressed mRNA 
was determined by the 2-ΔΔCT method.28 The experiment 
was performed in triplicate, and average value was calcu-
lated for each sample.
DNA extraction and real-time quantitative methylation-
specific PCR 
Genomic DNA from 15 IgAN patients and 15 healthy con-
trols were treated by overnight proteinase K incubation, 
phenol-chloroform extraction, recovered by ethanol precip-
itation and RNase digestion. Sodium bisulfite conversion of 
unmethylated (but not methylated) cytosine residues to ura-
cil was performed as previously described.29 Briefly, 4 µg 
of genomic DNA were denatured in NaOH (0.3 M) for 20 
min at 50°C, and then diluted with 450 µL of a freshly pre-
pared solution of hydroquinone (125 mM) and sodium bi-
sulfite (2.5 M). After incubation for 3 hr at 70°C, modified 
DNA samples were desalted and purified through a column 
(Wizard DNA Clean-Up System, Promega, Madison, WI, 
USA), incubated with sodium hydroxide for 10 min at room 
temperature, precipitated with 100% ethanol, resuspended 
in 240 µL of water and stored at -80°C for real-time Quan-
titative Methylation-Specific PCR. 
The specific PCR was then used to distinguish between 
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from PBMCs using the Trizol re-
agent (Invitrogen, Carlsbad, CA, USA) in light of the man-
ufacturer’s instructions. The concentration and quality of 
RNA was analyzed spectroscopically using UV absorbance 
at 260 and 280 nm (A260/A280 ratio), and visualized by 
agarose gel electrophoresis individually. For RT-PCR, 2 μg 
total RNA was reverse- transcribed into cDNA with M-MLV 
reverse transcriptase by using oligo-dT as a primer. Real-
time PCR utilized SYBR green dye and Taq polymerase. 
One-tenth of the resulting cDNA template was used for the 
subsequent DNA amplification on a 7700 real-time PCR 
system apparatus. 
PCR conditions were 95°C for 15 min, followed by 95°C 
for 10 sec, 58°C for 30 sec, 72°C for 1 min repeated for 35 
cycles, and finally a 7-min incubation at 72°C. Serial dilu-
tions of the amplified product standard with a predefined 
known concentration were used to create a standard curve. 
The PCR primers for each gene in this analysis are given in 
Table 3. GADPH gene mRNA was used as the internal con-
trol. The primers for GAPDH were 5’-CCA TGG AGA AGG 
CTG GGG-3’ (sense), and 5’-CAA AGT TGT CAT GGA 
TGA CC-3’ (antisense) (250 bp). The thermal cycles were 
94°C for 6 min, followed by 35 cycles of 94°C for 60 sec 
58°C for 60 sec and 72°C for 60 sec, and finally 72°C for 
Table 2. Chromatin Immunoprecipitation Real-Time Quantitative PCR Primers Used for Validation of the CpG 
Array Data

















F, forward primer; R, reverse primer.
Table 3.  Primers Used in Real-Time Quantitative PCR for mRNA Expression
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significant methylation alterations were excluded in the tar-
get list if they were not identified as H3K4me3 targets. As a 
result, 321 probes displayed significant H3K4me3 differ-
ences in IgAN patients compared with healthy subjects. 
Among these probes, 154 probes displayed increased H3K-
4me3 and 167 probes showed decreased H3K4me3. The 
H3K4me3 alterations of the 20 selected genes are presented 
in Table 5. Among these were genes that are involved in 
many cellular pathways and critical biological functions in-
cluding protein transcription and synthesis, transport, cell 
apoptosis, etc.
Validation for CpG microarray data
To validate the microarray results, two genes that displayed 
increased H3K4me3 (FCRL4 and GALK2) and two de-
creased H3K4me3 (PTPRN2 and IL1RAPL1) were select-
ed and verified by ChIP-qPCR. The data showed FCRL4 
(1.56±0.02 versus 1.0; p<0.05) and GALK2 (2.53±0.03 ver-
sus 1.0; p<0.05) were significantly higher in IgAN patients 
than those in healthy controls, while PTPRN2 (0.68±0.03 
versus 1.0; p<0.05) and IL1RAPL1 (0.52±0.03 versus 1.0; 
p<0.05) were significantly lower in IgAN patients than those 
in healthy controls (Fig. 1). All these results together sup-
ported the accuracy of the array data. 
H3K4me3 alterations and gene expression
The mRNA expressions of the four selected H3K4me3 
candidates were examined by real-time quantitative RT-
methylated and unmethylated DNA sequences. The primer 
sequences for the methylated form and unmethylated form 
are given in Table 4. The PCR conditions comprised one in-
cubation of 10 min at 95°C, followed by 35 cycles of 94°C 
for 40 sec, 60°C for 30 sec, and 72°C for 30 sec, and a final 
extension at 72°C for 10 min. Relative enrichment of DNA 
methylation for each gene was determined by the same 
method described above. The experiment was performed in 
triplicate and obtained CT values to calculate methylation 
index (MI=methylated copy number/(methylated copy 
number+unmethylated copy number).30
Statistical analysis
Statistical analyses were performed using SPSS software, 
version 11.5 (SPSS Company, Chicago, IL, USA). Quantita-
tive data were expressed as means±SD, and p values less 





Identification of CpG island methylation profiles 
between IgAN patients and healthy subjects
Two steps were adopted to analyze this data to avoid false 
positive results. First, genes that showed significant differenc-
es (the ratio >2 or <0.5) between IgAN and control groups 
were regarded as H3K4me3 candidates. Second, genes with 
Table 4. Primers Used for Quantitative Methylation-Specific PCR
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versus 1.0; p<0.05) displayed lower mRNA expression lev-
els. According to our previous understanding, the high lev-
els of H3K4me3 are associated with active genes,11,31 but 
the high expression of IL1RAPL1 was contrary to its low 
H3K4me3.
PCR. As shown in Fig. 2, FCRL4 (1.86±0.03 versus 1.0; p 
<0.05), GALK2 (1.73±0.04 versus 1.0; p<0.05) and IL-
1RAPL1 (1.55±0.03 versus 1.0; p<0.05) mRNA expression 
levels in PBMCs were significantly higher than in corre-
sponding normal subjects. In addition, PTPRN2 (0.74±0.03 
Table 5. The 20 Selected Probes with H3K4me3 Alterations between Immunoglobulin A Nephropathy Patients and Healthy 
Subjects, Identified by Chromatin Immunoprecipitation-CpG Microarray Analysis
Probe ID Fold 
change Within Genome location Description
UHNhscpg0001983 8.577 CLK2 chr1:153500080-153500610 CDC-like kinase 2 isoform 1
UHNhscpg0008170 5.366 HIST1H4F chr6:26348814-26348966 H4 histone family, member C
UHNhscpg0006479 4.939 FCRL4 chr1:155816513-155816958 Fc receptor-like 4
UHNhscpg0006702 4.366 CSNK1A1 chr5:148911195-148911493 Casein kinase 1, alpha 1 isoform 1
UHNhscpg0006894 3.790 CDA08 chr16:45868451-45868589 T-cell immunomodulatory protein
UHNhscpg0004054 3.664 KDELR2 chr7:6471769-6471934 KDEL receptor 2
UHNhscpg0000596 3.637 AP2A2 chr11:959952-961029 Adaptor-related protein complex 2, alpha 2 subunit
UHNhscpg0004573 3.202 PGD chr1:10382314-10382599 Phosphogluconate dehydrogenase
UHNhscpg0010927 2.362 MTAP chr9:21985297-21986139 Methylthioadenosine phosphorylase
UHNhscpg0010976 2.324 GALK2 chr15:47400563-47401266 Galactokinase 2 isoform 2
UHNhscpg0001857 0.482 PTPRN2 chr7:157408680-157409362 Protein tyrosine phosphatase, receptor type, N
UHNhscpg0010123 0.432 IL1RAPL1 chrX:28955949-28956013 Interleukin 1 receptor accessory protein-like 1
UHNhscpg0010772 0.427 ACYP2 chr2:54250449-54250542 Muscle-type acylphosphatase 2
UHNhscpg0005499 0.414 SSBP2 chr5:80779204-80779324 Single-stranded DNA binding protein 2
UHNhscpg0006256 0.412 PTPN22 chr1:114201225-114201328 Protein tyrosine phosphatase, non-receptor type
UHNhscpg0010517 0.392 NMNAT2 chr1:181653529-181653673 Nicotinamide mononucleotide adenylyltransferase
UHNhscpg0003883 0.342 STK32C chr10:133896317-133896418 Protein kinase (PKE)
UHNhscpg0004752 0.325 GJB2 chr13:19663948-19664549 Gap junction protein, beta 2, 26kDa (Connexin 26) 
UHNhscpg0001735 0.316 PTBP1 chr19:749886-750913 Polypyrimidine tract-binding protein 1 isoform
UHNhscpg0001251 0.315 PISD chr22:30387570-30388248 Phosphatidylserine decarboxylase
H3K4me3, H3 lysine 4 trimethylation.
Fig. 1. Quantitative real-time PCR verification of ChIP-chip result. Real-time 
PCR values are expressed as the mean±SD compared to the healthy 
group. Quantitative data was calculated by 2
-ΔΔCT. Assays were done in trip-
licate. *p<0.05 was considered statistically significant (independent sam-
ples t-test). Microarray changes of histone H3 lysine 4 trimethylation are 
presented as upregulated (U) or downregulated (D) compared to the 
healthy group. ChIP-chip, chromatin immunoprecipitation linked to micro-
arrays analysis; IgAN, IgA Nephropathy.
Fig. 2. H3 lysine 4 trimethylation (H3K4me3) variations and mRNA expres-
sion levels with real-time quantitative RT-PCR analysis. Relative mRNA val-
ues are expressed as the mean±SD compared to the healthy group. 
Quantitative data was calculated by 2
-ΔΔCT. Assays were done in triplicate. 
*p<0.05 was considered statistically significant (independent samples t-
test). Microarray changes of histone H3K4me3 are presented as upregulat-
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ily. PTPs are known to be signaling molecules that regulate 
a variety of cellular processes including cell growth, differ-
entiation, mitotic cycle, and oncogenic transformation.37 
Protein tyrosine kinase (PTK) can promote renal podocytes 
to produce vascular endothelial growth factor by a signal-
ing pathway and increase urine protein.38 In our results, PT-
PRN2 displayed decreased H3K4me3 and mRNA expres-
sion. It has been elucidated that PTP can oppose PTK 
actions.39 Perhaps the depression of PTP could not inhibit 
the activity of PTK and exacerbate the progression of IgAN. 
PTPRN2 has been a sensitive and specific DNA methyla-
tion marker panel for squamous cell lung cancer.40 In our 
study, PTPRN2 gene also showed high DNA methylation.
The protein encoded by the IL1RAPL1 gene is a mem-
ber of the interleukin 1 receptor family and is similar to the 
interleukin 1 accessory proteins. The IL-1 cytokine family 
is considered to play important roles in the progression of 
IgAN, and IL-1 is expressed in the glomeruli of IgAN pa-
tients.41 Generally, cytokines fulfill their biological process-
es by combination with their receptor. IL1RAPL1 showed 
low methylation of H3K4me3, enhanced DNA methylation 
and increased mRNA expression. We feel that the high ex-
pression can encode for more interleukin 1 receptors and 
deteriorate the disease. The low levels of H3K4me3 and 
high level DNA methylation are generally associated with 
inactive genes; nevertheless, IL1RAPL1 displayed high 
mRNA expression. We assumed that there are other epigen-
etic modifications to promote this gene expression.
DNA methylation and histone modification may act syn-
H3K4me3 alterations and DNA methylation
We further assessed the association of H3K4me3 and DNA 
methylation. As shown in Fig. 3, the levels of DNA methyl-
ation in PTPRN2 (0.75±0.04 versus 0.26±0.01; p<0.05) 
and IL1RAPL1 (0.59±0.04 versus 0.34±0.01; p<0.05) were 
higher than in normal subjects. FCRL4 (0.46±0.02 versus 
0.71±0.09; p<0.05) was lower than in normal subjects. How-
ever, GALK2 (0.38±0.03 versus 0.44±0.104; p>0.05) showed 
no distinct difference in DNA methylation between IgAN 
and normal subjects. 
DISCUSSION
More than one-half of human genes have cytosineguanine 
(CpG) islands which are important regulatory elements of 
transcription.32 In this study, we used human 12K CpG is-
land arrays to identify H3K4me3 variations. The human 
12K CpG island contains a significant percentage of the 
CpG islands found in the human genome and approximate-
ly 68% were located near a transcription start site.33 Among 
the genes identified in the CpG array, FCRL4 and GALK2 
displaying increased H3K4me3 were selected for further 
study. The FCRL4 gene encodes a member of the immuno-
globulin receptor superfamily and is one of several Fc re-
ceptor-like glycoproteins clustered on the long arm of chro-
mosome 1. Data indirectly suggest that FcalphaRI (Fc alpha 
receptor I) activation mediates IgAN development by initi-
ating a cytokine/chemokine cascade.34 The encoded protein 
by FCRL4 may have a similar function as the FcalphaRI in 
the pathogenetic progress. As for the Fc receptor-like gly-
coproteins, we conjecture that they take part in the underga-
lactosylation of IgA in some way.
The abnormalities of galactosylation and sialylation in 
IgA1 play an important role in the development of IgA ne-
phropathy. Mesangial deposits of IgA contains high con-
centrations of abnormally glycosylated IgA1, characterized 
by undergalactosylation.35 The GALK2 gene plays a key 
role in normal galactose metabolism by catalyzing the con-
version of α-d-galactose to galactose 1-phosphate.36 Our re-
sults showed its high expression of mRNA, and we may 
hypothesize that the increase in GALK2 induces the low 
concentration of galactose and results in the undergalacto-
sylation of IgA.
Two other genes, PTPRN2 and IL1RAPL1, demonstrat-
ed decreased H3K4me3. The protein encoded by PTPRN2 
is a member of the protein tyrosine phosphatase (PTP) fam-
Fig. 3. The relationship between H3 lysine 4 trimethylation (H3K4me3) alter-
ations and DNA methylation levels. DNA methylation index values are ex-
pressed as the mean±SD compared to the healthy group. Assays were 
done in triplicate. *p<0.05 was considered statistically significant (indepen-
dent samples t-test). Microarray changes of histone H3K4me3 are present-
ed as upregulated (U) or downregulated (D) compared to the healthy 
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